Fulcrum Therapeutics, Inc.
General ticker "FULC" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $350.0M (TTM average)
Fulcrum Therapeutics, Inc. follows the US Stock Market performance with the rate: 54.2%.
Estimated limits based on current volatility of 6.5%: low 8.52$, high 9.70$
Factors to consider:
- Total employees count: 51 (-32.9%) as of 2024
- Top business risk factors: Economic downturns and volatility, Regulatory and compliance, Commercialization challenges, Funding access, Marketing effectiveness
- Current price 44.5% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.25$, 6.06$]
- 2025-12-31 to 2026-12-31 estimated range: [1.95$, 5.19$]
Financial Metrics affecting the FULC estimates:
- Positive: with PPE of -20.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.79 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 93.22 > 63.39
- Positive: Investing cash flow per share per price, % of 11.46 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
Short-term FULC quotes
Long-term FULC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $6.34MM | $2.81MM | $80.00MM |
| Operating Expenses | $118.90MM | $113.47MM | $101.90MM |
| Operating Income | $-112.56MM | $-110.66MM | $-21.90MM |
| Non-Operating Income | $2.69MM | $13.33MM | $12.17MM |
| R&D Expense | $76.78MM | $71.80MM | $63.39MM |
| Income(Loss) | $-109.87MM | $-97.33MM | $-9.72MM |
| Profit(Loss)* | $-109.87MM | $-97.33MM | $-9.72MM |
| Stockholders Equity | $198.94MM | $235.19MM | $243.03MM |
| Assets | $226.69MM | $257.69MM | $260.72MM |
| Operating Cash Flow | $-97.05MM | $-90.97MM | $-2.22MM |
| Capital expenditure | $1.96MM | $0.51MM | $0.28MM |
| Investing Cash Flow | $12.41MM | $-36.69MM | $32.23MM |
| Financing Cash Flow | $84.32MM | $118.12MM | $2.75MM |
| Earnings Per Share** | $-2.44 | $-1.59 | $-0.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.